Lilly USA, LLC Launches New Rotation Programme for Medical Students
Lilly USA, LLC has launched a new rotation programme for aspiring physicians. The rotation assignments cut across different aspects of the pharmaceutical company's business — from drug discovery and development to bioethics and patient safety — providing third- and fourth-year medical students a lens into the pharmaceutical industry, its vision and focus on improving patient outcomes.
Students from Tulane University School of Medicine will be the first to participate in the pilot programme at Eli Lilly and Company's Indianapolis headquarters.
"We're excited to kick off the Medical Student Rotation Programme," said Yolanda Johnson-Moton, director of external relations, US Medical Division, Lilly. "The students selected for this program distinguished themselves, both academically and during the interview process.
"The programme is intensive and exposes these future practitioners to the various scientific and medical phases of the drug development process, along with a holistic view of the company. Students have a unique vantage point and opportunity to work alongside some of the most talented health care professionals in the industry, including physicians, and understand their important roles in our organisation."
The Medical Student Rotation Programme is a 4-week experiential learning programme. In partnership with Tulane University School of Medicine, medical students will gain experience and understanding of drug development and how physicians at Lilly contribute to the process. The programme features a student-centric curriculum and structured mentorship in various aspects of pharmaceutical development. This includes independent projects, industry-led workshops, exposure to many facets of drug discovery and development and networking opportunities with Lilly medical leaders.
"Students participating in the programme will get hands-on knowledge of the many roles physicians play in the pharmaceutical industry," said Dr Marc J. Kahn, senior associate dean for admissions and student affairs at Tulane University School of Medicine. "The partnership between Lilly and Tulane matches Lilly's commitment to medical education with Tulane's passion for providing exciting educational experiences for our students. Tulane has the largest combined MD/MPH programme in the country, a successful MD/MBA programme and a programme in medical innovation. This experience combined with Lilly's reputation as a leader in the pharmaceutical industry makes the partnership a natural one."
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance